NATIONAL RURAL UTILITIES COOPERATIVE FINANCE CORP /DC/
NRUCNYSE
$22.64
↑ +0.0%Jul 17 close · end-of-day
Price
1Y↓ -0.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
—
Enterprise Value
—
P/E
—
P/S
—
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
—
Dividend Yield
—
Revenue (TTM)
—
Net Income (TTM)
$119.9M
Free Cash Flow (TTM)
—
Gross Margin
—
Operating Margin
—
Net Margin
—
ROE
3.9%
ROIC
—
Debt / Equity
11.1
Net Cash
-$33.8B
Return 1Y
-0.7%
Company profile
NephroGenex, Inc. is a pharmaceutical company, which focuses on the development of therapeutics to treat kidney disease, an area of significant unmet medical need. It is developing Pyridorin, a small molecule drug that is acting inhibitor of the pathogenic oxidative chemistries which are elevated in diabetic patients. The company was founded by Billy G. Hudson, J. Wesley Fox Ahmann and Tryggvason Karl on May 25, 2004 and is headquartered in Raleigh, NC.
- CEO
- J. Andrew Don
- Sector
- Finance, Insurance, And Real Estate
- Industry
- Banking
- Employees
- 1,700
- Headquarters
- Virginia
- Website
- www.nephrogenex.com
Earnings
NRUC Q3 2026 Earnings
Period ends 2026-02-28
MetricActualYoY
Revenue——
Diluted EPS——
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | — | — | — | — | — |
| Net income | $811.7M | $795.8M | $501.5M | $553.3M | $139.7M |
| Diluted EPS | — | — | — | — | — |
| Operating cash flow | $240.0M | $250.8M | $337.8M | $320.6M | $207.5M |
| Free cash flow | — | — | — | — | — |
| Gross margin | — | — | — | — | — |
| Operating margin | — | — | — | — | — |
| Net margin | — | — | — | — | — |
| Line item | Q4 '24 | Q1 '24 | Q2 '24 | Q3 '25 | Q4 '25 | Q1 '25 | Q2 '25 | Q3 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | — | — | — | — | — | — | — | — |
| Net income | $145.6M | -$163.8M | $144.4M | $86.0M | $73.1M | $4.8M | $19.6M | $22.4M |
| Diluted EPS | — | — | — | — | — | — | — | — |
| Operating cash flow | $53.4M | $36.7M | $63.8M | $150.3M | -$43.3M | $82.3M | $38.9M | $105.6M |
| Free cash flow | — | — | — | — | — | — | — | — |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | — | — | — | — | — | — | — | — |
| Net margin | — | — | — | — | — | — | — | — |
Company news
Apr 16, 2026
Jan 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.